Teva: Conservatively Bottom-Fishing For Extra Income - Even If Recovery Is Far Off

Background

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) is the largest generic drug maker in the world with a presence in 80 countries, and is the largest publicly held company in Israel. Its drug portfolio is diversified and vast containing over 1800 molecules used in diagnostics and treatment over a wide variety of health issues. Teva's R&D has a particular focus on a variety of central nervous system disorders. The company's size and the scope of its vast medicines portfolio allow for economies of scale and distribution and marketing synergies.

Total revenues over the last 5 years have been fairly steady; they have varied little from $20 billion, and grown only 7.8% over the period. However they are poised to take a hit from the blockbuster Teva drug Copaxone going off patent recently, a drug that under patent protection had provided 35% of Teva's profit. Accretion from the recent Actavis acquisition is still an unknown at this point.

READ FULL ARTICLE HERE

It's on us. Share your news here.

Submit your stories and articles to citybizlist today.